Figure 4

Sensitisation of carcinoma cells to chemotherapeutic agents by EG3287. (A, B) A549 and DU145 cells were incubated in medium containing 5% serum with 5-FU at the indicated concentrations in the absence or presence of 100 μ M EG3287. Cell numbers were determined after a 3-day incubation. ^*P<0.05; ^**P<0.01 for 5-FU alone vs 5-FU plus EG3287. (C, D) A549 and DU145 cells were incubated in serum-free medium containing 5-FU at the indicated concentrations in the absence or presence of 100 μ M EG3287. Cell viability was measured after 48 h of treatment. ^*P<0.05; ^**P<0.01; and ^***P<0.001 for the chemotherapeutic drug alone vs drug plus EG3287. (E) Left, total cellular proteins were extracted from breast carcinoma MDA-MB-453 and lung carcinoma A549 cells and NRP1 was detected by immunobloting. Right: MDA-MB-453 cells were incubated in serum-free medium containing 5-FU at the indicated concentrations in the absence or presence of 100 μ M EG3287. Cell viability was measured after 48 h of treatment. (F, G) A549 and DU145 cells were incubated in serum-free medium containing paclitaxel or cisplatin at the indicated concentrations in the absence or presence of 100 μ M EG3287. Cell viability was measured after 48 h of treatment. ^*P<0.05; ^**P<0.01; and ^***P<0.001 for the chemotherapeutic drug alone vs drug plus EG3287. (H) Small interference RNA-transfected A549 cells were incubated in serum-free medium containing 5-FU or paclitaxel at the indicated concentrations for 48 h prior to viability measurement. ^*P<0.05; ^**P<0.01; and ^***P<0.001 vs control (C) siRNA-transfected cells.